A Pillar Of Eisai’s Growth Strategy Misses Primary Endpoint In First Phase III Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Eisai-acquired Morphotek lead candidate farletuzumab sees disappointing results in platinum-sensitive ovarian cancer.